Hepatitis B virus(HBV) infection is a global public health problem,with an estimated 350 million people worldwide chronically infected and approximately 500000 who die annually from HBV-related liver diseases.Manageme...Hepatitis B virus(HBV) infection is a global public health problem,with an estimated 350 million people worldwide chronically infected and approximately 500000 who die annually from HBV-related liver diseases.Management of chronic HBV is challenging and waves of guidelines emerge every year.One of the hottest topics and a matter of debate is the management of patients in their early immunotolerant phase of infection.With the lack of evidence,dealing with this particular subset of patients creates a great conflict with opposing views.In this review,the author highlights the pros and cons of these views and proposes a reasonable solution to resolve this dilemma.展开更多
文摘Hepatitis B virus(HBV) infection is a global public health problem,with an estimated 350 million people worldwide chronically infected and approximately 500000 who die annually from HBV-related liver diseases.Management of chronic HBV is challenging and waves of guidelines emerge every year.One of the hottest topics and a matter of debate is the management of patients in their early immunotolerant phase of infection.With the lack of evidence,dealing with this particular subset of patients creates a great conflict with opposing views.In this review,the author highlights the pros and cons of these views and proposes a reasonable solution to resolve this dilemma.
